Cairn Therapeutics
  • About
  • CT-262
  • Opportunity
  • Contact

Introduction to CT-262

A compound with these five characteristics would be a major advance in the treatment of cancer.

Picture

CT-262 is a prodrug delivery system that selectively releases a highly cytotoxic moiety intracellularly in cancer cells, sparing healthy cells.
​

  • Active moiety is an analogue of duocarmycin with highly potent antitumor activity

  • Novel design – nothing like it examined previously - creates potential for major advance in the treatment of cancer

  • Prodrug is inactive and highly stable in plasma, greatly limiting the potential for off-target toxicity

  • Selective intracellular release in cancer cells of toxic duocarmycin moiety – free drug - from prodrug driven by protein in cytosol of cancer cells that does not appear to be meaningfully present in healthy cells

  • Targeting of cancer cells not dependent upon presence of cell surface antigen – all cancer cells targeted
 
  • CT-262 highly efficacious in in vivo xenograft and transgenic cancer models, as well as in organoid models highly predictive of efficacy in humans
 
  • Low toxicity, low myelosuppression that typically limits chemotherapy
 
  • Not subject to traditional mechanisms of resistance (unable to raise resistance to date)


​Combination of results from preclinical efficacy studies and safety evaluations demonstrate CT-262 is highly efficacious and broadly active, and suggests the compound has a wide therapeutic window.
​

CT-262 is a Prodrug That is Selectively Activated in Cancer Cells
​and Targets DNA to Induce Programmed Cell Death

CT-262 is an analogue of duocarmycin, a natural product with potent anti-tumor activity.  
Picture
Picture

CT-262 Undergoes a Two-Step Process for Selective Activation Inside Cancer Cells Delivering Primed Drugs Selectively to Cancer Cells

Picture
Picture

Contrast With Traditional Chemotherapy – Potential for Wide Therapeutic Window

Picture
Picture

Selective Activation Shown in Mice with Breast Cancer: Inactive Prodrug is Converted to Primed Drug in Breast Cancer Tissue but Not in Normal Breast Tissue
​

Picture
Picture

Highly Potent & Broadly Active in a Range of Human Cancers

Data demonstrate CT-262 is readily converted from inactive form to cytotoxic form in human cancers.
Picture
Picture

CT-262 Shows Pronounced Activity Against Highly Resistant Human NSCLC ​in Murine Xenograft Model 

CT-262 inhibits tumor growth in a dose-dependent manner and continues inhibition after the last dose.
Picture
Picture

CT-262 is Highly Potent, Efficacious and Broadly Active in Organoid Models of Cancer ​that are Predictive of Human Efficacy

Data demonstrate CT-262 is readily converted from inactive form to cytotoxic form in human cancers.
Picture
Picture

CT-262 Should Be Much Less Susceptible to Cancer Cell Resistance Mechanisms Than Leading Therapies  

Picture
Picture

The promise of CT-262

Picture
Copyright © Cairn 2023
  • About
  • CT-262
  • Opportunity
  • Contact